FOLD - Amicus Therapeutics EPS misses by $0.01 misses on revenue

Amicus Therapeutics (FOLD): Q1 GAAP EPS of -$0.25 misses by $0.01.Revenue of $66.4M (+9.7% Y/Y) misses by $5.35M.2021 Financial GuidanceFor the full-year 2021, the Company anticipates total Galafold revenue of $300 million to $315 million. Double-digit revenue growth in 2021 is expected to be driven by continued operational growth and commercial execution across all major markets, including the U.S., EU, U.K. and Japan.Non-GAAP operating expense guidance for the full-year 2021 is $410 million to $420 million, driven by continued investment in the global Galafold launch, AT-GAA clinical studies and pre-launch activities, and advancing our gene therapy pipeline.2Cash, cash equivalents, and marketable securities totaled $417.4 million at March 31, 2021. Based on current operating models, the Company believes that the current cash position and expected future revenues are sufficient to fund the Company’s operations and ongoing research programs through to self-sustainability.Press Release

For further details see:

Amicus Therapeutics EPS misses by $0.01, misses on revenue